A Study of IBI362 in Participants With Obesity or Overweight for Weight Loss
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This is a study of IBI362 in participants with overweight and obesity. The main purpose is to
learn more about how IBI362 affects body weight. The study period including 4-8 weeks dose
titration and 40-44 weeks maintain treatment and 12 weeks follow up.